Leading Physician-Scientist Dr. William F. Regine Named Senior Associate Dean for Clinical Affairs at UM School of Medicine and President of UM Faculty Physicians, Inc.

An International Expert in Radiation Oncology, Dr. Regine will continue as Chair of the Department of Radiation Oncology

University of Maryland School of Medicine (UMSOM) Dean Mark T. Gladwin, MD announced today that William F. Regine, MD, FACR, FASTRO, FACRO has been appointed to the executive role of Senior Associate Dean for Clinical Affairs at the University of Maryland School of Medicine (SOM), effective immediately.

An internationally renowned physician-scientist known for his work in the use of stereotactic radiosurgery (SRS), as well as for his research efforts with gastrointestinal and central nervous system malignancies, Dr. Regine currently is the Isadore & Fannie Schneider Foxman Chair of Radiation Oncology, and Executive Director of the Maryland Proton Treatment Center (MPTC).

In his new role, Dr. Regine will serve as UMSOM’s chief physician, overseeing clinical care, business, and other matters related to the School’s clinical faculty. In conjunction with the Dean, he will lead UMSOM-wide clinical initiatives, while developing business and delivery strategies for the clinical mission involving in-patient and out-patient practices.

He also will meet regularly with senior leadership at the University of Maryland Medical Center (UMMC) and the University of Maryland Medical System (UMMS) to solve problems, review opportunities, and strengthen relationships, while serving as a senior liaison between UMSOM and the Veterans Administration Medical Center on clinical initiatives.

Concurrently, in his appointment as the new President of University of Maryland Faculty Physicians, Inc. (FPI), Dr. Regine will lead strategic efforts in financial growth and success for this organization, made up of more than 1,200 UMSOM faculty members, who provide care to more than 1.5 million outpatients and inpatients every year. FPI treats patients at more than 60 offices located across Maryland, as well as delivering all clinical care at UMMC and several other UMMS hospitals.

Dr. Regine will retain his position as Executive Director of the MPTC, where he leads the first and most advanced facility of its kind in the Baltimore-Washington, DC region, providing nearly 2,000 cancer patients a year with precise, "pencil-beam" technology to treat solid tumors. He also will remain Chair of the Department of Radiation Oncology, a post he has held since 2003. The department, which has pioneered radiation treatment in cancer, has achieved a Top 5 national ranking in National Institutes of Health research funding.

“Dr. Regine is an exemplary academic and clinical leader in the School of Medicine, who has established a consistent model for growth and success in the clinical enterprise over many years” said Dean Gladwin, who also is Vice President for Medical Affairs, University of Maryland, Baltimore, and the John Z. and Akiko K. Bowers Distinguished Professor. “He is ideally suited to serve in these critical senior executive roles, while continuing his leadership in the Department of Radiation Oncology.”

Dr. Regine earned his MD degree at the State University of New York Health and Science Center at Syracuse, served his radiation oncology residency at Thomas Jefferson University Hospital in Philadelphia, and completed a fellowship in radiation oncology-head and neck and gastrointestinal malignancies at Thomas Jefferson University and University of Florida Hospitals. Prior to joining UMSOM, he held a joint appointment as a Professor of Surgery and Neurosurgery at the University of Kentucky in Lexington, KY.

A highly recognized researcher, Dr. Regine has served as principal or co-principal Investigator in four National Cancer Institute (NCI)-sponsored cooperative group clinical trials. He has been a member of the GI and Brain Tumor steering committees for NRG Oncology, the NCI sponsored national cooperative clinical trials group, and has been the chairman of the GI section of the National Oral Board examination for trainees in radiation oncology. His efforts in these roles have helped define new standards of cancer care. Additionally, he has been the principal investigator and study chairman for two institutional clinical trials that have introduced novel standards of care for patients with brain metastases and malignant spinal cord compression.

Dr. Regine is the co-editor of Principles and Practices of Stereotactic Radiosurgery, the first comprehensive textbook of its kind, and is the author of more than 150 peer-reviewed articles and book chapters. He also is the co-inventor of the GammaPod, a groundbreaking treatment device completely dedicated to the stereotactic radiation treatment of early-stage breast cancer.

For his work, Dr. Regine has received numerous honors and awards, including the American Cancer Society’s MileOne Visionary Award in 2021, the Daily Record Health Care Heroes 2019 “Lifetime Achievement Award” in 2019, the University of Maryland, Baltimore’s (UMB) Entrepreneur of the Year in 2016, and the American Board of Radiology’s Lifetime Volunteer Service Award in 2015. He also was named a "Top Doctor" in the specialty of Radiation Oncology by Baltimore Magazine and "Super Doctor" in the Mid-Atlantic by Washington Post Magazine over multiple years.

"I am excited to take on these new responsibilities," said Dr. Regine. "Our vision is to build an integrated multi-specialty clinical enterprise of excellence, in alignment with our UMMC/UMMS and community partners, which further fuels excellence in our UMSOM academic missions."

About the University of Maryland School of Medicine

Now in its third century, the University of Maryland School of Medicine was chartered in 1807 as the first public medical school in the United States. It continues today as one of the fastest growing, top-tier biomedical research enterprises in the world -- with 46 academic departments, centers, institutes, and programs, and a faculty of more than 3,000 physicians, scientists, and allied health professionals, including members of the National Academy of Medicine and the National Academy of Sciences, and a distinguished two-time winner of the Albert E. Lasker Award in Medical Research. With an operating budget of more than $1.3 billion, the School of Medicine works closely in partnership with the University of Maryland Medical Center and Medical System to provide research-intensive, academic, and clinically based care for nearly 2 million patients each year. The School of Medicine has nearly $600 million in extramural funding, with most of its academic departments highly ranked among all medical schools in the nation in research funding. As one of the seven professional schools that make up the University of Maryland, Baltimore campus, the School of Medicine has a total population of nearly 9,000 faculty and staff, including 2,500 students, trainees, residents, and fellows. The combined School of Medicine and Medical System (“University of Maryland Medicine”) has an annual budget of over $6 billion and an economic impact of nearly $20 billion on the state and local community. The School of Medicine, which ranks as the 8th highest among public medical schools in research productivity (according to the Association of American Medical Colleges profile) is an innovator in translational medicine, with 606 active patents and 52 start-up companies. In the latest U.S. News & World Report ranking of the Best Medical Schools, published in 2021, the UM School of Medicine is ranked #9 among the 92 public medical schools in the U.S., and in the top 15 percent (#27) of all 192 public and private U.S. medical schools. The School of Medicine works locally, nationally, and globally, with research and treatment facilities in 36 countries around the world. Visit medschool.umaryland.edu